Welcome to the e-CCO Library!

P510: Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matos Coelho Bernardo, S.(1)*;Fernandes, S.(1);Serrazina, J.(1);Rodrigues, I.(1);Botto, I.(1);Bronze, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Santos, P.M.D.(1);Tato Marinho, R.(1);Correia, L.(1);
Created: Friday, 14 July 2023, 11:05 AM
P510: Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis
Year: 2022
Source: ECCO'22
Authors: Shehab, M.(1);Alrashed, F.(2);Heron, V.(3);Restellini, S.(4);Bessissow, T.(5);
Created: Friday, 11 February 2022, 3:56 PM
P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Schoenefuss*, P. Hoffmann

Created: Thursday, 21 February 2019, 9:14 AM
P510: Infliximab in the very young: it is all about the dosing – a multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Jongsma*1, D. Winter1, H. Huynh2, L. Norsa3, S. Hussey4, K-l. Kolho5, J. Bronsky6, A. Assa7, S. Cohen8, R. Lev-Tzion9, S. van Biervliet10, T. de Meij11, D. Shouval12, E. Wine2, V. Wolters13, A. Christiaens14, C. Martinez-Vinson15, L. de Ridder1

Created: Friday, 22 February 2019, 9:41 AM
P510: Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure
Year: 2021
Source: ECCO'21 Virtual
Authors: Parlanti, D.(1);Poggioli, G.(1);Cardelli, S.(1);Tanzanu, M.(1);Boschi, L.(1);Rottoli, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P510: Skin anergy and latent tuberculosis in inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Herrera de Guise*, V. Robles, N. Borruel, E. Navarro, F. Casellas

Created: Friday, 22 February 2019, 9:49 AM
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bressler1, B. Sattin2, M.A. Williamson2, R. Khanna3, C.H. Seow4, D. Dajnowiec2, K. Karra2, L.L. Gao5, W. Afif6, mUST-Decide

Created: Thursday, 30 January 2020, 10:12 AM
P511: Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wolf D.*1, Lewis J.D.2, Siegmund B.3, Lichtenstein G.2, Sebastian S.4, Siegel C.A.5, Louis E.6, Haas T.7, Nedd K.8, Subramanian S.9, Aguilar H.10, Egan L.11, Gasche C.12, Doherty G.13, Lobo A.14, Spearman D.15, Patel A.16, Moparty R.17, Brookes M.18, Hebuterne X.19, Moum B.20, Dolin P.21

Created: Wednesday, 20 February 2019, 10:36 AM
P511: Disease-specific risk factors for malnutrition development in IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Einav, L.(1);Hirsch, A.(1,2);Ron, Y.(1,2);Aviv Cohen, N.(1,2);Anbar, R.(1,3);Lahav, S.(2);Maharshak, N.(1,2);Fliss Isakov, N.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P511: Early prediction of steroid failure in acute severe ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.C. Choy1,2,3*, K. Boyd4, R. Burder4, A. Gorelik5, R. Nallas6, J. Horvath6, Q. Lam6, N. Crinis6, D. Van Langenberg7, M. Sparrow8, W. Connell3, K. Visvanathan3,9, P. De Cruz1,2

Created: Thursday, 21 February 2019, 9:14 AM
P511: Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy
Year: 2022
Source: ECCO'22
Authors: Jijón, M.C.(1);Pujol-Muncunill, G.(1);Lozano Ruf, A.(1);Vila Miravet, V.(1);Alvarez Carnero, L.(1);García Arenas, D.(1);Egea Castillo, N.(1);Martín de Carpi, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P511: Evaluation of home faecal calprotectin testing to aid remote management and enhanced self-management of Inflammatory Bowel Disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Allen, K.(1)*;Munuswamy, P.(2);
Created: Friday, 14 July 2023, 11:05 AM
P511: Radiological outcomes in perianal fistulising Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Lee*1, M. Kamm2, S. Bell2, M. Lust2, S. Brown2, E. Wright2, W. Connell2, E. Yong3, N. Ding2

Created: Friday, 22 February 2019, 9:41 AM
P511: Utilisation and efficacy of oral iron therapy in patients with iron deficiency anaemia in a nationwide cohort of ulcerative colitis patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Patel*1, N. Khan2

Created: Friday, 22 February 2019, 9:49 AM
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. XIAO1, P.L. Lakatos2, R. Bourdages3, A. Bitton2, W. Afif2, R. Kohen2, M. Berberi3, T. Bessissow2

Created: Thursday, 30 January 2020, 10:12 AM
P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.L. Winthrop1, G.Y. Melmed2, S. Vermeire3*, M.D. Long4, G. Chan5, R.D. Pedersen5, N. Lawendy5, A.J. Thorpe5, C.I. Nduaka5, C. Su5

Created: Thursday, 21 February 2019, 9:14 AM
P512: Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Watts G.*1, Arasaradnam R.2, Travis S.3, Sharma A.4, Awasthi A.5, Limdi J.6, Bishop-Bailey A.7, Mclain-Smith S.7, Finney-Hayward T.8

Created: Wednesday, 20 February 2019, 10:36 AM
P512: Results of interim analysis of a retrospective IGIBD study on adalimumab use in real practice in Italy: the REAL-life clinical effectiveness of ADAlimumab in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Pugliese1, M. Mendolaro2, R. D'Incà3, D. G. Ribaldone4, M. Principi5, C. Ricci6, E. Stasi7, M. L. Scribano8, G. Bodini9, S. Saibeni10, A. C. Privitera11, D. Simondi12, A. Armuzzi1, M. Daperno*2, Italian Group for Inflammatory Bowel Disease (IGIBD)1

Created: Friday, 22 February 2019, 9:41 AM
P512: Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Jansen, F.M.(1);Smits, L.S.(1);Thomas, P.W.A.(1);den Broeder, N.(1);de Jong, D.J.(1);van Dop, W.A.(1);Hoentjen, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P512: The counts of white blood cells are not predictive for long-term remission under treatment with thiopurines: a three year Japanese multi-center retrospective cohort study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kiyohara, H.(1,2)*;Yamazaki, H.(3);Moriya, K.(4);Akimoto, N.(5);Kawai, S.(6);Kobayashi, T.(1);
Created: Friday, 14 July 2023, 11:05 AM